Related Experiment Video
Updated: Jul 4, 2026
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
A TSP-1 synthetic peptide inhibits bleomycin-induced lung fibrosis in mice
Abstract:
Bleomycin showed toxicity to lung and was recognized to induce a well model of lung fibrosis. Activated alveolar macrophages released increased amounts of transforming growth factor-beta1(TGF-beta1) in response to bleomycin-induced lung injury. Thrombospondin-1(TSP-1) was involved in the activation of latent TGF-beta1(L-TGF-beta1) through the association of the TSP-1/L-TGF-beta1 complex with the cell receptor of TSP-1, CD36. The antagonistic effects of the synthetic peptides were studied by the administration of TSP-1 (447-452) synthetic peptides to the mouse model. The hydroxyproline contents of the TSP-1-treated groups were significantly lower than those of other experimental groups. Inflammation, fibrotic degree and distribution of collagen fibers in the interstitial and alveolar in the TSP-1-treated groups were less than those of the other experimental groups. The expressions of collagen I and III in TSP-1-treated groups were significantly lower than in the other experimental groups. TSP-1 synthetic peptide reduced the tissue fibrotic pathologies and collagen accumulation in the model, resulting in the decreased severity of bleomycin-induced lung injury.
Insights
Synthetic peptides targeting Thrombospondin-1 (TSP-1) effectively reduced lung fibrosis in a bleomycin-induced mouse model. This intervention mitigated inflammation and collagen deposition, offering a potential therapeutic strategy for lung injury.
Area of Science:
- Pulmonary Medicine
- Fibrosis Research
- Molecular Biology
Background:
- Bleomycin is a known inducer of lung fibrosis and toxicity.
- Activated alveolar macrophages release transforming growth factor-beta1 (TGF-beta1) during bleomycin-induced lung injury.
- Thrombospondin-1 (TSP-1) facilitates latent TGF-beta1 activation via CD36.
Purpose of the Study:
- To investigate the antifibrotic effects of TSP-1 (447-452) synthetic peptides.
- To evaluate the impact of TSP-1 peptides on bleomycin-induced lung injury in a mouse model.
Main Methods:
- Administration of TSP-1 (447-452) synthetic peptides to a bleomycin-induced mouse model.
- Measurement of hydroxyproline content as a marker of fibrosis.
- Histological assessment of inflammation, fibrotic degree, and collagen fiber distribution.
- Analysis of collagen I and III expression levels.
Main Results:
- TSP-1 treated groups showed significantly lower hydroxyproline content.
- Reduced inflammation, fibrotic degree, and collagen deposition were observed in TSP-1 treated groups.
- Significantly lower expression of collagen I and III in TSP-1 treated groups compared to controls.
Conclusions:
- TSP-1 synthetic peptides effectively ameliorate bleomycin-induced lung fibrotic pathologies.
- The study demonstrates the potential of TSP-1 modulation as a therapeutic approach for lung fibrosis.
- Reduced collagen accumulation and tissue damage are key outcomes of TSP-1 peptide treatment.
